Flinn, a provider of AI-powered software designed to automate regulatory and quality processes in medtech, has raised $20 million in additional funding. The round was led by HV Capital, with participation from BHI – Bertelsmann Healthcare Investments, and continued support from existing investors Cherry Ventures, Speedinvest, and SquareOne.

The funding comes as healthcare systems globally face increasing pressure from ageing populations, more complex treatment approaches, and administrative challenges that are placing strain on public healthcare budgets. Innovation in these sectors is shaped by strict regulatory and quality frameworks.

Flinn aims to address these challenges through AI-based software that automates regulatory workflows, data evaluation, and reporting, replacing manual processes with more scalable systems. The company plans to expand its platform beyond existing regulatory and post-market solutions to cover earlier development stages as well as commercial processes, creating a unified compliance and quality framework across the full medical product lifecycle. The company also plans to use the funding to support international growth, including further expansion across Europe and entry into the US market.

By integrating automation into regulatory and quality functions, the platform aims to improve operational efficiency, shorten development timelines, and maintain compliance while supporting patient safety requirements. The approach is intended to reduce administrative burden and allow teams to focus more on product development and innovation.